Participant flow

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants receive a protocol-approved chemotherapy regimen based on the participant and/or physician preference. Participants then receive a protocol-approved adjuvant endocrine therapy for 5-10 years in the absence of disease progression or unacceptable toxicity.

   id

   FG000

   title

   Chemo and Endocrine Therapy

2. description

   Participants receive a protocol-approved endocrine therapy for 5-10 years in the absence of disease progression or unacceptable toxicity.

   id

   FG001

   title

   Endocrine Therapy Alone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         25

      2. group Id

         FG001

         num Subjects

         28

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         12

      2. group Id

         FG001

         num Subjects

         7

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         175

      2. group Id

         FG001

         num Subjects

         93

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         70

      2. group Id

         FG001

         num Subjects

         111

      type

      Disease progression

   5. reasons

      1. group Id

         FG000

         num Subjects

         42

      2. group Id

         FG001

         num Subjects

         41

      type

      Other reason

   6. reasons

      1. group Id

         FG000

         num Subjects

         24

      2. group Id

         FG001

         num Subjects

         19

      type

      Delinquent data

   7. reasons

      1. group Id

         FG000

         num Subjects

         33

      2. group Id

         FG001

         num Subjects

         29

      type

      Reason under review

   8. reasons

      1. group Id

         FG000

         num Subjects

         626

      2. group Id

         FG001

         num Subjects

         632

      type

      On treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         2511

      2. group Id

         FG001

         num Subjects

         2507

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1504

      2. group Id

         FG001

         num Subjects

         1547

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1007

      2. group Id

         FG001

         num Subjects

         960

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

9383 participants were screened and 5083 were randomized to the trial: 2547 to the Chemo and Endocrine Therapy arm and 2536 to the Endocrine Therapy Alone arm. In the Chemo and Endocrine Therapy Arm, 36 were ineligible. In the Endocrine Therapy Alone arm, 29 were ineligible. Ultimately, 5018 participants were eligible in the participant flow: 2511 in the Chemo and Endocrine Therapy arm and 2507 in the Endocrine Therapy Alone arm.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice